Antiplatelet and antithrombogenic effects of suloctidil.
Platelet aggregation induced in mice or rats by i.v. ADP can be antagonized by oral administration of suloctidil. This effect on platelet behaviour appears to be sufficient to reduce the rate of thrombotic occlusion of the femoral artery in the dog and to protect the rat against occurrence of thrombophlebitis.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors / Q000633:toxicity; D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D000882:Haplorhini; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010974:Platelet Aggregation / Q000187:drug effects*; D011412:Propanolamines / Q000494:pharmacology*; D051381:Rats; D013924:Thrombophlebitis / Q000517:prevention & control; D013927:Thrombosis / Q000517:prevention & control
D005343:Fibrinolytic Agents; D011412:Propanolamines; D000244:Adenosine Diphosphate; D001241:Aspirin